OGT hosts successful targeted sequencing workshop at ICHG/ASHG 2011

Tuesday 22 November 2011
Applications:
1320140601

Oxford Gene Technology (OGT), provider of innovative genetics and biomarker solutions to advance molecular medicine, recently hosted a highly successful seminar at the International Congress of Human Genetics (ICHG) meeting in Montreal, Canada. The workshop, entitled “Adding value through analysis”, was well attended and outlined how the company’s Genefficiency™ Targeted Sequencing Service can be utilised to deliver rapid and cost-effective human genome analysis. The new service perfectly complements OGT’s portfolio of genomic and expression analysis tools, which are focused on providing meaningful results rather than insurmountable data sets. As well as ease-of-analysis, the new service provides high data-quality via OGT’s internationally-recognised probe design and independently-accredited quality management procedures.

For those that were unable to attend the meeting or want to know more, OGT has made the full presentation available online for free, where it can be viewed ‘on-demand’. Alternatively, to find out more about the full range of products and services offered by OGT, visit www.ogt.co.uk.

For further information, please contact:

Oxford Gene Technology, Begbroke Science Park, Sandy Lane, Yarnton, Oxford OX5 1PF
T:
+44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: products@ogt.co.uk

W: www.ogt.co.uk

Notes for editors:

About Oxford Gene Technology

Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative genetics research and biomarker solutions to advance molecular medicine.  The company has two trading businesses: Genomics comprises of CytoSure™ cytogenetics array, labelling and interpretation software products and services for the detection of chromosomal abnormalities, and Genefficiency™ Genomic Services, a unique combination of platforms, expertise and processing capabilities to deliver rapid, relevant genomic data. The Biomarkers business utilises proprietary next generation technologies to build a rich patent-protected portfolio of promising biomarkers for early stage cancer detection including advanced programmes in colorectal and prostate cancer plus the autoimmune disease systemic lupus erythematosus.

CytoSure™ and Genefficiency™ NGS browser: For Research Use Only; Not for Use in Diagnostic Procedures

CytoSure: This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.


Find out more

For more information about any OGT product or service, please contact us.